A Phase II Trial of Taxotere, Cisplatin, and Irinotecan in Advanced Esophageal and Gastric Cancer
- Taxotere, cisplatin and irinotecan will be administered to the patient once weekly for
2 weeks followed by a one week rest period (1 cycle is 3 weeks).
- Patients will also receive corticosteroids, intravenous hydration and anti-emetic
therapy prior to each treatment.
- A physical exam and bloodwork will be done each week of the treatment and every 2
cycles, reassessment of the tumor by the same imaging method to determine the baseline
size will be conducted.
- Patients will remain on the study unless disease progression or intolerable toxicity
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).
Peter C. Enzinger, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|Faulkner Hospital||Jamaica Plain, Massachusetts 02130|